PTPN2 and neoplasm: Using OT-I TCR transgenic T cells and an ovalbumin (OVA)-expressing AT3 mammary tumour cell model, these investigators determined that Ptpn2−/− CD8+ T cell ACT enhanced tumour clearance compared to the control T cell ACT [27].